1272666-89-3

Basic information

• Product Name: 2-(3-((7-oxabicyclo[2.2.1]heptan-1-yl)methoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
• Synonyms: 2-(3-((7-oxabicyclo[2.2.1]heptan-1-yl)methoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
• CAS NO: 1272666-89-3
• Molecular Weight: 330.232
• Mol File: 1272666-89-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-(3-((7-oxabicyclo[2.2.1]heptan-1-yl)methoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-((7-oxabicyclo[2.2.1]heptan-1-yl)methoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane(1272666-89-3)
• EPA Substance Registry System: 2-(3-((7-oxabicyclo[2.2.1]heptan-1-yl)methoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane(1272666-89-3)

Safety Data

• Hazardous Substances Data: 1272666-89-3(Hazardous Substances Data)

Upstream product

• 22428-85-9 4-Methylencyclohexanol 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 946402-76-2 1-(iodomethyl)-7-oxabicyclo[2.2.1]heptane 
• 214360-76-6 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol 
• 29648-66-6 4-methylenecyclohexanone 
• 51656-90-7 8-methylene-1,4-dioxaspiro[4.5]decane 

Downstream Products

• 1272667-39-6 ((1S,4S)-4-(5-(3-(7-oxabicyclo[2.2.1]heptan-1-ylmethoxy)phenyl)-4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexyl)methanol 
• 1272667-38-5 (1S,4S)-4-(5-(3-(7-oxabicyclo[2.2.1]heptan-1-ylmethoxy)phenyl)-4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexanecarbaldehyde 
• 1272667-52-3 5-(3-(7-oxabicyclo[2.2.1]heptan-1-ylmethoxy)phenyl)-7-((1s,4s)-4-(azidomethyl)cyclohexyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine 
• 1272670-06-0 5-(3-(7-oxabtcyclo[2.2.1]heptan-1-ylmethoxy)phenyl)-7-((1S,4S)-4-(aminomethyl)cyclohexyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine 

Relevant articles and documents

Optimisation of a 5-[3-phenyl-(2-cyclic-ether)-methyl-ether]-4-aminopyrrolopyrimidine series of IGF-1R inhibitors

Taking the pyrrolopyrimidine derived IGF-1R inhibitor NVP-AEW541 as the starting point, the benzyl ether back-pocket binding moiety was replaced with a series of 2-cyclic ether methyl ethers leading to the identification of novel achiral [2.2.1]-bicyclic ether methyl ether containing analogues with improved IGF-1R activities and kinase selectivities. Further exploration of the series, including a fluorine scan of the 5-phenyl substituent, and optimisation of the sugar-pocket binding moiety identified compound 33 containing (S)-2-tetrahydrofuran methyl ether 6-fluorophenyl ether back-pocket, and cis-N-Ac-Pip sugar-pocket binding groups. Compound 33 showed improved selectivity and pharmacokinetics compared to NVP-AEW541, and produced comparable in vivo efficacy to linsitinib in inhibiting the growth of an IGF-1R dependent tumour xenograft model in the mouse.

ETHER DERIVATIVES OF BICYCLIC HETEROARYLS

The invention relates to compounds of formula (I), wherein the substituents are as defined in the specification; to processes for the preparation of such compounds; pharmaceutical compositions comprising such compounds; such compounds as a medicament; such compounds for the treatment of a proliferative disease